REDWOOD CITY, CA / ACCESSWIRE / July 10, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced the launch of a new cardiac monitoring pilot program with a prominent hospital group encompassing 60 sites spread across multiple states.
Biotricity's cardiac monitoring solution is the only three-channel connected solution in the world. This unique technology results in superior diagnostics, reduced patient risk, and enhanced workflow efficiency, providing improved clinical outcomes while lowering overall healthcare costs. Additionally, it significantly increases provider revenue by five times compared to existing solutions, making it an exceptional choice both clinically and financially.
"The addition of this latest pilot program positions us to accelerate adoption of our products and underscores the growing demand for advanced cardiac monitoring solutions," said Dr. Waqaas Al-Siddiq, founder and CEO of Biotricity. "This new pilot program provides us with a significant opportunity to showcase the effectiveness of our technology in diverse healthcare settings. By working closely with the active sites, we aim to refine our approaches and further validate the benefits of our solutions for both patients and healthcare providers. This collaboration is another vital step forward in our strategy to revolutionize cardiac care on a global scale."
Building on the momentum of previous pilot programs, Biotricity will collaborate closely with healthcare professionals at these 60 sites to enhance patient interaction protocols and optimize data collection processes. This latest pilot program aims to demonstrate the transformative potential of Biotricity's advanced technology suite in improving cardiac patient outcomes and streamlining healthcare delivery across a broader geographic region.
With a strategic focus on a $35 billion market opportunity, Biotricity is well-positioned to transform cardiac care, both in the clinic and in the home. For more information about Biotricity and its innovative healthcare solutions, please visit Biotricity.
About Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com and follow us on Twitter and LinkedIn.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events, or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to several risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
Investor Relations Contacts
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.40 |
Daily Change: | -0.02 -3.98 |
Daily Volume: | 230 |
Market Cap: | US$8.930M |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB